Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation

C. Martínez; C. Canals; B. Sarina; E. P. Alessandrino; D. Karakasis; A. Pulsoni; S. Sica; M. Trneny; J. A. Snowden; E. Kanfer; N. Milpied; A. Bosi; S. Guidi; C. A. De Souza; R. Willemze; R. Arranz; L. Jebavy; A. Hellmann; D. Sibon; R. Oneto; J. J. Luan; P. Dreger; L. Castagna; A. Sureda

doi:10.1093/annonc/mdt206

Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation

C. Martínez, C. Canals, B. Sarina, E. P. Alessandrino, D. Karakasis, A. Pulsoni, S. Sica, M. Trneny, J. A. Snowden, E. Kanfer, N. Milpied, A. Bosi, S. Guidi, C. A. De Souza, R. Willemze, R. Arranz, L. Jebavy, A. Hellmann, D. Sibon, R. OnetoJ. J. Luan, P. Dreger, L. Castagna, A. Sureda

Research output: Contribution to journal › Article › peer-review

Abstract

Background: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard of care for patients with relapsed Hodgkin's lymphoma (HL). However, there is currently little information on the predictors of outcome for patients whose disease recurs after ASCT. Methods: Five hundred and eleven adult patients with relapsed HL after ASCT from EBMT-GITMO databases were reviewed. Results: Treatments administered following ASCT failure included conventional chemotherapy and/or radiotherapy in 294 (64%) patients, second ASCT in 35 (8%), and alloSCT in 133 (29%). After a median follow-up of 49 months, overall survival (OS) was 32% at 5 years. Independent risk factors for OS were early relapse (

Original language	English
Article number	mdt206
Pages (from-to)	2430-2434
Number of pages	5
Journal	Annals of Oncology
Volume	24
Issue number	9
DOIs	https://doi.org/10.1093/annonc/mdt206
Publication status	Published - Sep 2013

Keywords

Autologous stem cell transplantation
Hodgkin's lymphoma
Relapse

ASJC Scopus subject areas

Oncology
Hematology

Access to Document

10.1093/annonc/mdt206

Cite this

Martínez, C., Canals, C., Sarina, B., Alessandrino, E. P., Karakasis, D., Pulsoni, A., Sica, S., Trneny, M., Snowden, J. A., Kanfer, E., Milpied, N., Bosi, A., Guidi, S., De Souza, C. A., Willemze, R., Arranz, R., Jebavy, L., Hellmann, A., Sibon, D., ... Sureda, A. (2013). Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. Annals of Oncology, 24(9), 2430-2434. [mdt206]. https://doi.org/10.1093/annonc/mdt206

Martínez, C, Canals, C, Sarina, B, Alessandrino, EP, Karakasis, D, Pulsoni, A, Sica, S, Trneny, M, Snowden, JA, Kanfer, E, Milpied, N, Bosi, A, Guidi, S, De Souza, CA, Willemze, R, Arranz, R, Jebavy, L, Hellmann, A, Sibon, D, Oneto, R, Luan, JJ, Dreger, P, Castagna, L & Sureda, A 2013, 'Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation', Annals of Oncology, vol. 24, no. 9, mdt206, pp. 2430-2434. https://doi.org/10.1093/annonc/mdt206

@article{556aecf481c74d78a97006195edb4a8f,

title = "Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation",

abstract = "Background: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard of care for patients with relapsed Hodgkin's lymphoma (HL). However, there is currently little information on the predictors of outcome for patients whose disease recurs after ASCT. Methods: Five hundred and eleven adult patients with relapsed HL after ASCT from EBMT-GITMO databases were reviewed. Results: Treatments administered following ASCT failure included conventional chemotherapy and/or radiotherapy in 294 (64%) patients, second ASCT in 35 (8%), and alloSCT in 133 (29%). After a median follow-up of 49 months, overall survival (OS) was 32% at 5 years. Independent risk factors for OS were early relapse (",

keywords = "Autologous stem cell transplantation, Hodgkin's lymphoma, Relapse",

author = "C. Mart{\'i}nez and C. Canals and B. Sarina and Alessandrino, {E. P.} and D. Karakasis and A. Pulsoni and S. Sica and M. Trneny and Snowden, {J. A.} and E. Kanfer and N. Milpied and A. Bosi and S. Guidi and {De Souza}, {C. A.} and R. Willemze and R. Arranz and L. Jebavy and A. Hellmann and D. Sibon and R. Oneto and Luan, {J. J.} and P. Dreger and L. Castagna and A. Sureda",

year = "2013",

month = sep,

doi = "10.1093/annonc/mdt206",

language = "English",

volume = "24",

pages = "2430--2434",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "NLM (Medline)",

number = "9",

}

TY - JOUR

T1 - Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation

AU - Martínez, C.

AU - Canals, C.

AU - Sarina, B.

AU - Alessandrino, E. P.

AU - Karakasis, D.

AU - Pulsoni, A.

AU - Sica, S.

AU - Trneny, M.

AU - Snowden, J. A.

AU - Kanfer, E.

AU - Milpied, N.

AU - Bosi, A.

AU - Guidi, S.

AU - De Souza, C. A.

AU - Willemze, R.

AU - Arranz, R.

AU - Jebavy, L.

AU - Hellmann, A.

AU - Sibon, D.

AU - Oneto, R.

AU - Luan, J. J.

AU - Dreger, P.

AU - Castagna, L.

AU - Sureda, A.

PY - 2013/9

Y1 - 2013/9

N2 - Background: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard of care for patients with relapsed Hodgkin's lymphoma (HL). However, there is currently little information on the predictors of outcome for patients whose disease recurs after ASCT. Methods: Five hundred and eleven adult patients with relapsed HL after ASCT from EBMT-GITMO databases were reviewed. Results: Treatments administered following ASCT failure included conventional chemotherapy and/or radiotherapy in 294 (64%) patients, second ASCT in 35 (8%), and alloSCT in 133 (29%). After a median follow-up of 49 months, overall survival (OS) was 32% at 5 years. Independent risk factors for OS were early relapse (

AB - Background: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard of care for patients with relapsed Hodgkin's lymphoma (HL). However, there is currently little information on the predictors of outcome for patients whose disease recurs after ASCT. Methods: Five hundred and eleven adult patients with relapsed HL after ASCT from EBMT-GITMO databases were reviewed. Results: Treatments administered following ASCT failure included conventional chemotherapy and/or radiotherapy in 294 (64%) patients, second ASCT in 35 (8%), and alloSCT in 133 (29%). After a median follow-up of 49 months, overall survival (OS) was 32% at 5 years. Independent risk factors for OS were early relapse (

KW - Autologous stem cell transplantation

KW - Hodgkin's lymphoma

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=84883333182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883333182&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdt206

DO - 10.1093/annonc/mdt206

M3 - Article

C2 - 23712545

AN - SCOPUS:84883333182

VL - 24

SP - 2430

EP - 2434

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 9

M1 - mdt206

ER -

Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this